Aardvark reports ARD-201 preserved lean mass, reduced weight; WE-868 shows >10% weight loss in mCRC patients

Aardvark Therapeutics, Inc.

ARD-201 (ARD-101+sitagliptin) in DIO mice reduced body weight ~19% in 30 days, comparable to high-dose tirzepatide, and preserved lean mass.
In Phase 2a, ARD-101 reduced hunger (CoEQ) and showed weight control signals, well-tolerated with no serious AEs in 14 adults with obesity.
WE-868 (OxPhos modulator) induced >10% average weight loss in mCRC patients over median 10 weeks; in DIO mice, weight loss exceeded semaglutide at 50 mg/kg.
Aardvark plans to start Phase 2 POWER trial (weight regain prevention) for ARD-201 by end 2025; investor webinar scheduled for Nov 5.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.